Answers are grounded in this paper and cite their sources.
Breast cancer is a major cause of cancer-related mortality worldwide, with a high incidence and significant healthcare burden. Despite the central role of chemotherapy, its effectiveness is hindered by systemic toxicity, drug resistance, and recurrence, underscoring the need for improved drug delivery strategies. This study investigates PDA-functionalised SiO₂@MoS₂ nanocomposites as carriers for DOX loading and pH-responsive release, together with their associated in vitro cellular responses. PMS was fabricated via a mussel-inspired coating strategy and thoroughly characterised to confirm successful core–shell construction and surface functionalization. Colloidal characterisation revealed formulation-dependent responses in serum-containing medium, with PMSD exhibiting a lower reported hydrodynamic diameter and PDI than MSD at 48 h. We evaluated the effects of the main loading parameters (pH, contact time, carrier dosage, and initial DOX concentration) and applied kinetic and isotherm models to describe the loading behaviour. Under the optimised conditions (drug-to-carrier ratio of 1:1, pH 6, 24 h), PMS achieved a DOX entrapment efficiency of 82% and a loading capacity of 820 mg g⁻¹. The in vitro release was pH-responsive, reaching approximately 82% at pH 5 compared with 54% at pH 7.4 within 24 h. Early-stage release was described using Higuchi and Korsmeyer–Peppas analyses. Their combined interpretation supported a diffusion-related contribution together with formulation and pH-dependent departures from a simple diffusion-only description. The DOX-loaded nanocomposites exhibited pronounced antiproliferative activity against breast cancer cells, while unloaded PMS maintained high viability in BJ-1 fibroblasts and MCF-10A breast epithelial cells across the tested concentration range following 24 h of exposure. Increased MDA levels and NAC-mediated attenuation of oxidation-sensitive fluorescence, accompanied by partial recovery of viability, supported an oxidative-stress contribution to PMSD-associated cytotoxicity. These findings demonstrate that PMS hybrid nanocomposites provide an efficient drug delivery platform for breast cancer treatment by integrating controlled release with cytotoxicity associated with increased intracellular oxidative activity.
No takes yet. Share an insight, caveat, or question.
Elmowafy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: